Yahoo · Oct 19, 2026
Stocktwits Pharma Pulse: Moderna-Merck Cancer Vaccine Grabs Spotlight As Kidney-Cancer And MS Data Pour In
Humacyte, Vera, Maze and Climb Bio will present dialysis-access and kidney-disease findings at ASN Kidney Week.
RC
NYSE · RCUS
Arcus Biosciences, Inc.
Healthcare · Biotechnology
$23.75
Down-$3.11 (-13.09%)
Updated Oct 21, 2026, 5:37 PM
SID Score
5.2/10
Composite research score
Smart Money
58/100
Neutral
- Market cap
- 2.72B
- P/E ratio
- -7.68
- Dividend yield
- 0.00%
- 52-week range
- $16.35 – $31.74
- Volume
- 6.24M
- Avg. volume
- 1.53M
Price performance · RCUS
RCUS price history
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 20, 2026
RCUS closed at $23.75 after 21 trading sessions, down 11.61% for the selected period.
- Last close
- $23.75
- Period change
- -11.61%
- Period low
- $22.12
- Period high
- $26.87
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 20, 2026 | $21.26 | $24.70 | $20.81 | $23.75 | 6.24M |
| Oct 19, 2026 | $22.44 | $22.94 | $21.37 | $22.14 | 3.52M |
| Oct 16, 2026 | $22.79 | $22.955 | $21.60 | $22.12 | 1.43M |
| Oct 15, 2026 | $22.53 | $23.28 | $22.53 | $22.82 | 1.21M |
| Oct 14, 2026 | $22.82 | $23.47 | $22.36 | $22.53 | 1.21M |
| Oct 13, 2026 | $23.87 | $24.005 | $22.46 | $22.51 | 1.39M |
| Oct 12, 2026 | $24.42 | $24.73 | $24.12 | $24.34 | 1.34M |
| Oct 9, 2026 | $23.89 | $24.58 | $23.75 | $24.41 | 795.19K |
| Oct 8, 2026 | $24.29 | $24.38 | $22.80 | $23.83 | 1.86M |
| Oct 7, 2026 | $24.225 | $24.85 | $23.90 | $24.52 | 1.6M |
| Oct 6, 2026 | $24.96 | $24.96 | $23.96 | $24.28 | 824.85K |
| Oct 5, 2026 | $24.19 | $24.95 | $24.105 | $24.74 | 1.39M |
| Oct 2, 2026 | $25.48 | $25.58 | $24.09 | $24.44 | 1.04M |
| Oct 1, 2026 | $25.86 | $26.26 | $25.13 | $25.23 | 1.36M |
| Sep 30, 2026 | $26.18 | $26.35 | $25.56 | $25.83 | 1.36M |
| Sep 29, 2026 | $24.93 | $26.04 | $24.76 | $25.65 | 1.25M |
| Sep 28, 2026 | $24.85 | $25.505 | $24.35 | $25.01 | 1.25M |
| Sep 25, 2026 | $25.16 | $25.29 | $24.335 | $24.97 | 1.72M |
| Sep 24, 2026 | $26.20 | $26.49 | $24.42 | $25.06 | 2.04M |
| Sep 23, 2026 | $26.86 | $27.90 | $25.845 | $26.39 | 1.56M |
| Sep 22, 2026 | $26.34 | $27.11 | $26.04 | $26.87 | 1.39M |
Latest RCUS news
The latest Smart Investors Daily articles mentioning RCUS.
Stock researchCompany · Overview
Company
Market Activity
Research & News
RCUS research
Overview
Company profile and research snapshot.
Company profile
Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $29.50
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 16, 2026 | William Blair | Outperform | — |
| Oct 14, 2026 | JP Morgan | Overweight | — |
| Sep 30, 2026 | Wedbush | Outperform | — |
| Sep 16, 2026 | TD Cowen | Buy | — |
| Sep 8, 2026 | Truist Securities | Buy | — |
News briefing
No generated briefing is available yet.
Benzinga · Oct 16, 2026
William Blair Initiates Coverage On Arcus Biosciences with Outperform Rating
William Blair analyst Alethia Young initiates coverage on Arcus Biosciences (NYSE:RCUS) with a Outperform rating.
Fintel · Oct 14, 2026
JP Morgan Initiates Coverage of Arcus Biosciences at Overweight
Benzinga · Oct 14, 2026
JP Morgan Initiates Coverage On Arcus Biosciences with Overweight Rating, Announces Price Target of $41
JP Morgan analyst Priyanka Grover initiates coverage on Arcus Biosciences (NYSE:RCUS) with a Overweight rating and announces Price Target of $41.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
